Metabolic rewiring in cancer-associated fibroblasts is now central to breast cancer biology
Breast cancer progression is not dictated by malignant epithelial cells alone. The surrounding tumor microenvironment increasingly appears to function as an active metabolic partner, and cancer-associated fibroblasts sit near the center of that exchange. In this Frontiers in Immunology review, metabolic reprogramming in CAFs is presented as a core mechanism by which stromal cells support tumor growth, reshape immune function, and reinforce invasion and metastasis.
The logic is straightforward at the bedside even if the biology is intricate: when stromal fibroblasts shift into a metabolically activated state, they stop behaving like passive structural cells and begin feeding the tumor. They produce nutrients, remodel extracellular matrix, and secrete cytokines and growth factors that alter the surrounding tissue environment. In breast cancer, that creates a setting in which malignant cells receive both fuel and protection.
The review places this process in the context of breast cancer’s rising global burden and the limitations of treatment in a heterogeneous, adaptive tumor ecosystem. Molecular subtype remains clinically important, but subtype alone does not explain why some tumors invade aggressively, evade immunity, or resist therapy. CAF biology helps fill in that gap.
CAFs are not a single stromal cell type
A major theme of the review is heterogeneity. CAFs are not equivalent to normal fibroblasts, yet the boundary between them is not absolute. Normal fibroblasts maintain tissue structure and physiological homeostasis, while CAFs emerge from a spectrum of activated states with stronger pro-tumor behavior.
Multiple cellular sources can give rise to CAFs, including resident fibroblasts, quiescent pericytes, bone marrow-derived mesenchymal stem cells, hematopoietic stem cells, adipose-derived stem cells, epithelial cells through epithelial-mesenchymal transition, and endothelial cells through endothelial-mesenchymal transition. Tumor-derived signals, hypoxia, and reactive oxygen species all contribute to that conversion. Once activated, these fibroblasts participate in a reciprocal loop with cancer cells and the rest of the tumor microenvironment.
A single marker does not define the population cleanly. The review stresses that α-SMA, FAP, and FSP-1 are all used as activation markers, but each has limitations. Their expression can overlap with wound healing, fibrosis, pericytes, immune cells, or other mesenchymal compartments. The practical implication is important: CAF identification requires context, not a solitary immunostain.
One sentence captures the biological shift plainly. Normal fibroblasts become nutrient-supportive stromal accomplices once the breast tumor microenvironment reprograms their metabolism.
Glucose, amino acid, and lipid pathways converge on tumor support
The metabolic dimension of CAF biology is the main contribution of this review. CAFs undergo altered glucose, amino acid, and lipid metabolism, and those changes do more than sustain the fibroblast itself. They generate metabolites that can be exported to nearby tumor cells, forming a metabolic coupling arrangement that resembles a parasitic exchange.
In glycolysis-dominant CAFs, energy handling becomes tuned toward rapid substrate processing and metabolite release. The review describes altered expression of glucose transporter 1 and pyruvate dehydrogenase kinases in breast CAFs, with condition-dependent changes under hypoxia and normoxia. Those shifts reflect how deeply the stromal state is tied to oxygen tension and tumor demand. Under hypoxic pressure, the stromal compartment appears to adapt rather than simply fail.
The same principle extends beyond glucose. Amino acid and lipid remodeling add additional layers of support for tumor expansion, although the precise mechanisms remain under active investigation. The review is careful on this point: the field has mapped broad metabolic characteristics, but the exact causal pathways still need deeper work.
Immune suppression is built into the stromal program
Metabolic reprogramming in CAFs does not remain confined to nutrient handling. It also shapes the immune compartment. Through cytokines, chemokines, extracellular vesicles, and matrix remodeling, CAFs help establish an immunosuppressive microenvironment that is hostile to effective anti-tumor activity.
Inflammatory CAFs secrete mediators such as IL-6 and CXCL12, driving recruitment of suppressive immune cells. Myofibroblastic CAFs, marked by high α-SMA, contribute to extracellular matrix remodeling and physical reinforcement of the tumor niche. Antigen-presenting CAFs express MHC class II and CD74, influencing CD4+ T-cell function. The immune effect is not uniform across subtypes, but the direction of travel is consistent: the stromal compartment becomes less permissive to productive anti-tumor immunity.
A second blunt clinical reality follows from this. CAF-driven stromal remodeling can make a tumor harder to penetrate, harder to surveil, and harder to treat.
The review also describes a tumor-suppressive CAF subset, including SFRP4-positive CAFs that can inhibit breast cancer cell migration and epithelial-mesenchymal transition. This is an important reminder that CAFs are biologically diverse, and not every fibroblast-like stromal cell acts in the same direction. In human breast cancer, distinct CAF populations such as CAF-S1, CAF-S2, CAF-S3, and CAF-S4 have been defined by multiparameter marker analysis, with CAF-S1 and CAF-S4 enriched in more aggressive disease contexts such as TNBC and HER2-overexpressing tumors. CAF-S1 can also recruit CD4+CD25+ T cells and promote their differentiation into regulatory T cells through CXCL12, directly linking stromal signaling to immune suppression.
Why this matters for treatment resistance
The therapeutic relevance is obvious even though the review remains mechanistic rather than interventional. If CAFs feed tumor cells, remodel matrix, and suppress immunity, then they can blunt chemotherapy, endocrine therapy, targeted treatment, and immune-based approaches by several routes at once. The tumor is not simply adapting at the epithelial level; its stromal compartment is adapting alongside it.
That matters because current breast cancer treatment still leaves room for resistance, especially in biologically aggressive subtypes. A stromal cell that has switched to a nutrient-producing, matrix-remodeling, immune-modulating phenotype can help explain why some tumors persist despite treatment pressure. The review frames metabolic reprogramming as one of the key reasons CAFs have become such compelling therapeutic targets.
What the field still needs to prove
The review closes on a caution that is worth preserving. Many metabolic features of CAFs are now catalogued, but the specific mechanisms that drive each change are not fully defined. The field still needs deeper work on how glucose, amino acid, and lipid pathways are coordinated; how one CAF subtype differs from another in live human tumors; and how best to target these states without disrupting normal stromal repair.
Because this is a review, it does not provide trial data, response rates, or direct clinical outcomes. It instead maps a biologic framework that could guide future therapeutic design. The unanswered practical question is which metabolic node can be blocked without provoking unacceptable tissue toxicity or allowing the tumor to bypass the blockade through another stromal route.
For now, the review makes one point unmistakable: breast cancer progression is not only a cancer-cell story. It is also a fibroblast metabolism story, and the stroma may be one of the most durable drivers of malignancy in the disease.